Investigating bleeding events related to platelet transfusion triggers for central venous catheters
Changes in Central Venous Catheterization Bleeding Events After Implementing a Lower Trigger For Platelet Transfusion - an Observational Study
This study is testing if lowering the platelet count needed before placing a central venous catheter can help reduce serious bleeding in patients with blood disorders.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Region Skane Academic / other |
| Locations | 1 site (Lund, Lunds universitet) |
| Trial ID | NCT06187831 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the safety of lowering the preprocedural platelet transfusion trigger from 50x10^9/L to 10x10^9/L for patients undergoing central venous catheter (CVC) placement in a hematological setting. The study will analyze both retrospective and prospective data from adult patients at Skåne University Hospital in Lund, Sweden, focusing on the incidence of grade 3-4 postprocedural bleeding events. The change in transfusion trigger is based on updated practices and the use of ultrasound guidance, which may reduce bleeding complications. Approximately 110 CVCs are placed annually, and the study will monitor bleeding outcomes following the new protocol.
Who should consider this trial
Good fit: Ideal candidates include adult patients with hematological conditions requiring central venous catheter placement.
Not a fit: Patients who are not admitted to a hematological ward or those who die within 24 hours after CVC insertion may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to safer practices for platelet transfusions in hematological patients, potentially reducing unnecessary transfusions.
How similar studies have performed: Previous studies have explored similar approaches, but this specific change in transfusion trigger is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years of age * Indication for central venous catheter placement. * Patients admitted to a hematological ward at the current department Exclusion Criteria: * Death within 24h after insertion of CVC.
Where this trial is running
Lund, Lunds universitet
- Thomas Kander — Lund, Lunds universitet, Sweden (Recruiting)
Study contacts
- Principal investigator: Thomas Kander, PhD — Region Skåne Sweden
- Study coordinator: Thomas Kander, PhD
- Email: thomas.kander@med.lu.se
- Phone: +46 46 171163
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.